Nolvadex

Common Use

If the indication is used as adjuvant treatment, the recommended dose is 20 mg per day in one or two takes. It is currently recommended for the treatment course of at least 5 years. In the treatment of advanced forms, daily doses between 20 and 40 mg are used, depending on whether it is recommended to take one or two doses per day.

Precautions

The risk of developing endometrial cancer and uterine sarcoma (mostly malignant mixed Mullerian) is increased in the groups treated with tamoxifen, compared to a control group untreated and warrants careful gynecological monitoring.

Prevention of breast cancer with Nolvadex NZ (that is to say the administration of the product to women without diabetes) is not justified in the absence of efficacy to date.

– Due to the presence of lactose, this medicine is contraindicated in cases of congenital galactosemia, malabsorption of glucose and galactose or lactase deficiency.

– In the literature, it has been shown that individuals with CYP2D6 poor metabolisers have lower plasma levels of endoxifen, one of the most important active metabolites of tamoxifen contained in Nolvadex Online NZ and therefore the use of the drug in such patients should be extremely prudent.

Contraindications

• Pregnancy.
• Breastfeeding.
• Hypersensitivity to any component

Drug Interactions

Concomitant use with medications that inhibit CYP2D6 may lead to reduced concentrations of the active metabolite, endoxifen. Therefore potent inhibitors of CYP2D6 (eg paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should be avoided whenever possible during treatment with tamoxifen.

Combinations requiring precautions for use:

• Vitamin K: increased thrombotic and bleeding risk during tumor diseases. In addition, there may be possible interaction between oral anticoagulants and chemotherapy. More frequent monitoring of INR is recommended.
• Cytotoxic agents: increased risk of thromboembolic events.

Possible Side Effects

• Increased frequency of endometrial abnormalities (pseudo-hyperplastic atrophy, hypertrophy, polyps, cancer) imposing a prompt and thorough investigation of any patient reporting of bleeding – (see section Special warnings and precautions for use).
• Infrequent impacts of endometrial cancers and rare cases of uterine sarcoma (mostly malignant mixed Mullerian) were reported.
• Cerebral ischemic vascular accidents and thromboembolic frequent, including deep thrombosis and pulmonary embolism. The risk of thromboembolism is increased when used in combination with cytotoxic agents.
• Visual disturbances including frequent cataracts, rare and / or frequent retinopathy corneal changes, and for which ophthalmologic monitoring is recommended.
• Cases of neuropathy and optic neuritis have been reported in patients receiving tamoxifen may be complicated by unilateral or bilateral blindness.
• Hot flashes and vulvar pruritus in connection with the anti-estrogen effect.
• Rare nauseous phenomena transferor splitting therapeutics.
• Some minor vaginal discharge.
• Skin manifestations: rash, urticaria. Rare cases of severe skin manifestations, such as erythema multiforme, bullous pemphigus, Stevens-Johnson syndrome, cutaneous vasculitis have been described.
• Frequently allergic reactions including angioedema.
• Alopecia.
• Headache.